Search

Additional file 3. Standardized scores of the QLQ-C30 and the QLQ-CR29 questionnaires.

Additional file 2. Survival cures for patients who received one course of radiotherapy (n = 11) and two courses of radiotherapy (n = 46). (A) Local progression-free survival; (B) distant metastasis-free survival; (C) progression-free survival; (D) cancer specific survival; (E) overall survival.

Additional file 1. Cancer-specific survival for patients who had clinical complete response (n = 42) after treatment and those who hadn’t (n = 15).

Additional file 1.

Additional file 1: Supplementary Figure 1. Flow diagram. Supplementary Figure 2. Impact of gene expression of UBE2W on various cancer survival in PrognoScan database. Overall survival (OS) of skin cancer(A), eye cancer (B), brain cancer (C, F, G), colorectal cancer (D), ovarian cancer (J), liver hepatocellular carcinoma (K), rectum adenocarcinoma (L), lung cancer (H). Relapse-free survival (RFS) of lung cancer (I). Disease-free survival (DFS) of colorectal cancer (E). Supplementary Figure 3. (A) UBE2W protein expression profile in the HPA database. (B) Network view of theUBE2W co-expression genes in breast cancer. (C) Correlation of UBE2W expression with various genes in BRCA in TIMER. Significant positive correlations by the Spearman test are marked with red color (p 0.05). Supplementary Figure 4. Expression and prognosis value of RBX1. (A) RBX1 expression in different cancers in TIMER (***P < 0.001). (B) RBX1 expression level in BRCA in Oncomine. (C) UBE2W expression in normal, tumor, metastatic tissues in TNMplot. (E, F) Overall survival and relapse-free survival analysis of RBX1in Kaplan-Meier Plotter. (G, H) Overall survival and relapse-free survival analysis of RBX1in PrognoScan. Supplementary Table 1. UBE2W expression in cancers vs normal tissue in Oncomine database (positive). Supplementary Table 2. Positive results associated with UBE2W expression in different cancers from the Prognoscan database. Supplementary Table 3. Correlation analysis between UBE2W and markers of infiltrating immune cells in TIMER. Supplementary Table 4. Correlation analysis between UBE2W and markers of infiltrating immune cells in GEPIA.

Additional file 1: Figure S1. The intensity of instability loci and the patient’s response to anti-PD-1 treatment. A. The representative PCR result of the colorectal cancer patient (case 6) with five microsatellite instability loci. B. The representative MRI images of the patient (case 6) showing a sigmoid colon mass before and after anti-PD-1 immunotherapy. Table S1. Univariate analyses of the prognostic factors for progression-free survival of the cohort (N = 33). Table S2. Multivariate Cox regression analyses of the prognostic factors for progression-free survival of the whole cohort (N = 33). Table S3. Univariate analyses of the location of the MSI loci for progression-free survival of the cohort (N = 33). Table S4. Multivariate Cox regression analyses for progression-free survival of the whole cohort (N = 33).

Additional file 1: Supplementary Figure 1. The flowchart of treatment of unresectable LACC. Abbreviations: MVR, multivisceral resection; EL, exploratory laparotomy; CME, complete mesocolic excision. Supplementary Figure 2. The surgical details of adjacent organs. Bladder (A); Small intestine (B). Supplementary Figure 3. Subgroup analysis of survival. OS analyzed in patients with unresectable LACC treated with NACRT and surgery by differentiation (A), Resection group (C), ypT stage (E), ypTNM stage (G), MVR (L), TRG score (M). PFS analyzed in all patients by differentiation (B), resection group (D), ypT stage (F), ypTNM stage (H). DFS analyzed in patients with radical surgery by KPS (I), Differentiation (J), VPLNI (K). P values in the figure were calculated from the comparison of the groups. NRS: Nonresectable surgery. Supplementary Table 1. Tumor characteristics and treatment of patients who abandoned surgery. Supplementary Table 2. Characteristics of studies included in the discussion. Supplementary Table 3. Univariate Cox analysis of prognostic factors for OS, PFS, DFS. Supplementary Table 4. 1. Multiple linear regression coefficients. 2. Correlation matrix analysis.

Additional file 1. S1: Characteristics of patients according to treatment group (non-matched cohort). S2: Number and location of distant metastasis in the matched groups. S3: Distant metastasis-free survival (A), non-regrowth disease-free survival (B), disease specific survival (C) and overall survival (D) for patients in the watch-and-wait group (N = 117). S4: Local recurrence-free survival (A), distant metastasis-free survival (B), disease-free survival (C), disease specific survival (D) and overall survival (E) for patients in the surgical group (N = 354).